Narhex float loses ground
Wednesday, 12 January, 2005
Shares in Sydney anti-viral drug developer Narhex Life Sciences' (ASX:NLS) made a promising debut this morning, listing at 4 cents above their $0.20 issue price. However they failed to maintain momentum, and at time of writing had dropped to $0.19.
Narhex -- the first biotechnology IPO for 2005 -- raised $8 million in the oversubscribed initial public offer of 40 million shares. The company announced yesterday it had signed an agreement with the US National Institute of Allergy and Infectious Diseases under which the NIH would evaluate its protease inhibitor Nar DG 35 for activity against Hepatitis C and SARS viruses. The NIH has already found Nar DG 35 to be moderately active against Hepatitis B protease.
New Zealand drug developer Neuren -- which was originally slated to float on January 11 - has issued a supplementary prospectus clarifying a number of points. The offer is scheduled to close on January 27 and is still fully subscribed. Neuren will now be listing on January 31.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
